Open Access

Transcriptome analysis of Klf15‑mediated inhibitory functions in a mouse deep venous thrombosis model

  • Authors:
    • Jin Zhou
    • Xueling Zhao
    • Shiwei Xie
    • Rudan Zhou
  • View Affiliations

  • Published online on: March 13, 2020     https://doi.org/10.3892/ijmm.2020.4538
  • Pages: 1735-1752
  • Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Krüppel‑like family (KLF) members are important regulators of proinflammatory activation in the vasculature. A transcriptome study involving RNA sequencing (RNA‑seq) and quantitative PCR (qPCR) was performed to investigate Klf15 and Klf15‑regulated gene levels in C57BL/6 mice with inferior vena cava thrombi and in control (Blank) mice. A total of 2,206 differentially expressed genes (DEGs), including 1,330 upregulated and 876 downregulated genes, were identified between the deep venous thrombosis (DVT) group and the Blank group. Additionally, 1,041 DEGs (235 upregulated and 806 downregulated) were identified between the Klf15‑small interfering RNA (siRNA) and Klf15‑negative control (NC) groups. The DEGs were subjected to Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses, and qPCR was conducted to validate the results. A total of seven significant DEGs were selected from the RNA‑seq results. Matrix metalloproteinases (Mmp)12, Mmp13, Mmp19, Arg1, Ccl2, heme oxygenase‑1 and Fmo3 levels were significantly higher, while Klf15 levels were lower, in the DVT group than in the Blank group. Fmo3 and Mmp19 have not been previously identified as DVT‑associated DEGs. Klf15, Mmp12 and Mmp13 levels were compared between the Klf15‑siRNA and Klf15‑NC groups. Mmp12 and Mmp13 expression was significantly higher, while that of Klf15 was lower, in the Klf15‑siRNA group than in the Klf15‑NC group. Critical roles of Klf15, Mmp12 and Mmp13 have been identified, which have not previously been shown to help regulate DVT initiation and progression. Moreover, Klf15‑mediated regulation of DVT may be modulated by downregulation of various genes, such as Mmp12 and Mmp13, potentially providing a theoretical foundation and diagnostic criteria for DVT treatment.

Introduction

Deep venous thrombosis (DVT) is one of the most common vascular diseases and is associated with high mortality and complex therapeutic processes (1). Thrombolytics and interventional therapies are still the mainstream treatments for DVT, but they are limited by a low cure rate and a high postoperative recurrence rate (2). The current therapeutic methods are restricted, especially regarding the prolonged time for diagnosis and treatment (3). Considering the complex mechanisms and various regulatory factors of DVT, studies on DVT have focused on the underlying regulatory genes, providing a valuable foundation for the diagnosis and treatment of DVT (4-6).

Krüppel-like factor 15 (Klf15), a transcriptional regulatory factor, is involved in various pathophysiological processes, such as cell differentiation, apoptosis and tumor formation, which are closely related to cardiovascular diseases such as hypertension, atherosclerosis and coronary heart disease (4). Klf15 is widely expressed in tissues and organs, especially in the heart, liver, kidneys and skeletal muscles (7). Lu et al (8) reported that similarly to other members of the KLF family, Klf15 inhibits NF-κB activation in vascular smooth muscle by interacting with p300 (Klf15-p300), thereby inhibiting down-stream target genes and inflammatory responses. Moreover, the expression level of Klf15 significantly decreased in mouse aortic smooth muscle cells treated with the oxidized component POVPC and human atherosclerotic tissues, which revealed that Klf15 plays a key role in the formation of atherosclerosis (7,8). Studies revealing the relationship and the genetic interaction between DVT and Klf15 are urgently needed. Therefore, transcriptome analysis of Klf15 in a mouse inferior vena cava (IVC) thrombosis model was performed to identify the functions of Klf15 and its relationship with the regulatory process and formation of DVT.

High-throughput sequencing, or next-generation sequencing, is a novel genomic research technique characterized by high data output and involves RNA sequencing (RNA-seq); high-throughput sequencing can be utilized in the analysis of various transcriptional and functional regions (9). Strikingly, extensive data resources can be provided via high-throughput sequencing to enable the identification and screening of target genes or differentially expressed genes (DEGs) in the whole genome, which is important for analyzing the regulatory relationships between genes and disease pathogenesis (10).

Previous studies have investigated the role of Klf15 in atherosclerosis (8) and vascular smooth muscle cells (VSMCs) (11). Klf15 is a regulator of VSMC proinflammatory activation and overexpression of Klf15 can protect vascular endothelial cells against dysfunction (12). Although the pathogeneses of atherosclerosis and DVT are different, endothelial cells are important for both atherosclerosis and DVT. Disruption of the endothelium and the release of plaque constituents into the lumen of the blood vessel can trigger arterial thrombosis (13,14). Abnormal blood flow, altered properties of the blood itself and changes in the endothelium can trigger venous thrombosis. In contrast to what is observed in atherosclerosis, venous endothelial cells remain intact, but their dysfunction can trigger DVT (15). According to our knowledge, no reports have studied Klf15 in DVT. The research on Klf15 in atherosclerosis prompted the present study to hypothesize that Klf15 can protect against DVT by affecting venous endothelial cells. Preliminary experiments were performed in C57/BL/6 mice and the results showed that inhibition of Klf15 induced DVT. In this study, the regulatory relationship and genetic interactions between DVT and Klf15 were investigated, revealing a new regulatory mechanism in a mouse model that could contribute to the diagnosis and treatment of DVT.

Materials and methods

Mouse and animal studies

The current study was performed with 40 C57BL/6 female mice (age, 8-10 weeks; weight, 20±3 g) that were purchased from the SPF animal laboratory of Kunming Medical University (Kunming, China). The mice were divided into four groups (n=10), according to a random grouping design. Then, the mice were fed at the experimental center of the SPF animal laboratory at Kunming Medical University with free access to food and water, a constant temperature of 21-25°C, a humidity level at 50-65%, under a 12-h light/dark cycle with proper ventilation. Next, a 2-3 week feeding period was conducted until the mice reached ≥25 g per mouse. The mice were observed twice daily to monitor their health and behavior. All animal experiments were performed following approval from the Animal Experiment and Ethics Committee of Kunming Medical University.

Generation of IVC thrombus in C57BL/6 mice

Once the weight of the mice exceeded 25 g, modeling of IVC thrombi in C57BL/6 mice was performed in each mouse except the Blank group. Mice were separated into four groups: The Blank group, the DVT group, the Klf15-NC group and the Klf15-small interfering (si)RNA group. The Blank and DVT groups were first generated, and mice in the DVT group underwent an operation to generate an IVC thrombus by utilizing a string to induce artificial stenosis of the IVC for thrombus formation (16). IVC thrombosis in mice was first modeled. After 24 h, the thrombi were acquired. During the perioperative period, the mice were monitored twice daily and they did not appear to be in distress or to exhibit obvious behavioral abnormalities. After the IVC thrombi were collected for further investigation, no other procedures were performed on the mice. Isoflurane was used as the inhaled agent to produce general anesthesia in mice. During the perioperative period of the experiment, the inhalant anesthetic isoflurane was utilized to induce and maintain general anesthesia to minimize animal pain and suffering and limit the discomfort that can accompany scientific research. Isoflurane was first used at 2% for induction and then at 1-1.5% for maintenance. Mice that have undergone IVC removal are likely to experience great pain and distress; thus, euthanasia was considered as the humane option. Euthanasia was conducted 24 h after the IVC thrombus operation. The mice were first anesthetized with 5% isoflurane until they stopped moving or appeared to be unconscious. Next, cervical dislocation was conducted, separating the cervical vertebrae from the skulls of the mice. An array of criteria was used to confirm the success of euthanasia, including arrest of pulse and breathing, lack of corneal reflex and inaudibility of respiratory sounds and heartbeat sounds upon examination with a stethoscope. The same process was performed for the IVC of the Klf15-NC and Klf15-siRNA groups, and there was an additional caudal vein injection with 0.9% normal saline (NS) in the Klf15-NC group and with Klf15 siRNA: 5′-CCT GTG AAG GAG GAA CAT T-3′ (Guangzhou RiboBio Co., Ltd.; 10 nmol per mouse) in the Klf15-siRNA group, which was performed 24 h before the operation. A total of 40 C57BL/6 mice were used in the present experiment, 36 of which were euthanized by cervical dislocation under anesthesia; four died due to hemorrhagic shock. The success of DVT modeling was judged by direct observations of the weights of the thrombi and vessels collected from the mice. In the present experiments, when 7-8 mm thrombi or vessels from mice were examined, most of the thrombi weighed >10 mg and most of the vessels weighed <10 mg.

RNA isolation and RNA-seq

On the basis of morphological experiments, thrombi in the IVC of mice and the vessels themselves were collected for examination. According to the manufacturer's protocol, RNA was extracted with TRIzol Reagent at 4°C. RNA purity was determined using a NanoPhotometer spectrophotometer (IMPLEN) and the concentration was measured using a Qubit RNA Assay kit in a Qubit® 2.0 Fluorometer (Thermo Fisher Scientific, Inc.). RNA integrity was assessed using the RNA Nano 6000 Assay kit of the Bioanalyzer 2100 system (Agilent Technologies, Inc.). Then, RNA degradation and contamination were monitored on 1% agarose gels. Furthermore, RNA purity was assessed using the RNA Nano 6000 Assay kit of the Bioanalyzer 2100 system (Agilent Technologies, Inc.). Thus, qualified RNA was used as a material for later analyses and provided samples for RNA-seq.

RNA-seq data and bioinformatics analysis

High-throughput sequencing was used to obtain and identify raw reads in samples. Further evaluation of the quality of the clean reads was performed to discard low-quality reads, which had either >50% of bases with a Q value ≤20 or >5% unrecognized sequences ('N'). After obtaining the high-quality clean reads, the reads were mapped to the human reference genome to enable downstream gene analysis.

For analysis of the expression levels of transcripts and the correlation of replicates, the fragments per kilobases per million mapped reads (FPKM) method was utilized in Pearson's correlation analysis to identify DEGs among each group of transcript sequences, which was determined by genetic length and the reads mapped to the human reference genome.

To detect the DEGs among the groups, DESeq2 was used, which provides statistical routines for determining differential expression in digital gene expression data using a model based on a negative binomial distribution. The resulting P-values were adjusted using Benjamini and Hochberg's approach for controlling the false discovery rate. Genes with an adjusted P<0.05 according to DESeq2 were considered differentially expressed.

GO enrichment analysis of DEGs was implemented by the clusterProfiler R package 3.14.3 (17), in which the gene length bias was corrected. GO terms with corrected P<0.05 were considered significantly enriched with DEGs. KEGG is a database resource used to elucidate the high-level functions and utilities of biological systems, such as the cell, organism and ecosystem, from molecular-level information, especially large-scale molecular datasets generated by genome sequencing and other high-throughput experimental technologies (http://www.genome.jp/kegg/). The clusterProfiler R package was used to test the statistical enrichment of DEGs in KEGG pathways.

qPCR analysis of DEGs

For validation of the expression of genes and the consistency of these two comparisons, qPCR analysis of DEGs was conducted according to the manufacturer's protocol for Maxima® SYBR-Green/ROX qPCR Master Mix (2X) (MBI Fermentas; Thermo Fisher Scientific, Inc.) on an ABI PRISM® 7300HT system (Applied Biosystems; Thermo Fisher Scientific, Inc.). The thermocycling conditions were as follows: Initial denaturation at 95°C for 10 min (1 cycle), followed by denaturation at 95°C for 15 sec and annealing and extension at 60°C for 60 sec (40 cycles). The primer sequences were obtained using the 2−∆∆Cq method (8) [ABI DataAssist™ v3.0 software (Thermo Fisher Scientific, Inc.)] and were as follows: KLF15 (77 bp) forward: 5′-CTT CCC TGA ATT TCT GTC-3′ and reverse: 5′-ATT CTT CAA TCT CCT CCA-3′; Mmp12 (88 bp) forward: 5′-CAG CAT TCC AAT AAT CCA A-3′ and reverse: 5′-GTA TGT CAT CAG CAG AGA-3′; Mmp13 (79 bp) forward: 5′-GTG ATG ATG ATG ATG ATG AC-3′ and reverse: 5′-GCA GGA TGG TAG TAT GAT T-3′; Arg1 (71 bp) forward: 5′-AAC ACG GCA GTG GCT TTA-3′ and reverse: 5′-TCA GTC CCT GGC TTA TGG-3′; Ccl2 (120 bp) forward: 5′-TGG GTC CAG ACA TAC ATT-3′ and reverse: 5′-ACG GGT CAA CTT CAC ATT-3′; Fmo23 (88 bp) forward: 5′-GAG TCT GGG ACG ATG GCT AC-3′ and reverse: 5′-GAG ATG GCG GTG GGT AAG-3′; heme oxygenase-1 (Hmox1) (88 bp) forward: 5′-TCA CAG ATG GCG TCA CTT-3′, and reverse: 5′-AGC GGT GTC TGG GAT GAG-3′; Mmp19 (113 bp) forward: 5′-GAT GCT GCC GTT TAC TCT-3′ and reverse: 5′-GGT TGG GCT CTA CTC TGT T-3′; β-actin (87 bp) forward: 5′-TAT GGA ATC CTG TGG CAT C-3′ and reverse: 5′-GTG TTG GCA TAG AGG TCT T-3′.

Statistical analysis

Prism 7 (GraphPad Software, Inc.) was used for all statistical analyses. The results from mouse thrombi (Figs. 1 and 6) are presented as the mean ± SEM. The experiments were repeated three times. An unpaired two-tailed Student's t-test between two groups was used for statistical significance of differences analyzed. P<0.05 was considered to indicate a statistically significant difference.

Results

Effect of Klf15 on thrombosis formation and the wet weight of the mouse thrombus

Klf15 has been shown to be critical for the initiation and progression of vascular inflammation (6). In this study, to identify the effects of Klf15 on DVT, morphological experiments were conducted on mice with IVC thrombi, which were divided into four groups: The Blank group, the DVT group, the Klf15-NC group with 0.9% NS caudal vein injection and the Klf15-siRNA group with Klf15-siRNA caudal vein injection (Table I). The vessels were removed from the mice of Blank group. If there was a blood clot blocking the vein based on direct observations (Fig. 1A), the clot was removed from the mouse for further examination (Fig. 1B). The results revealed that the weight of the thrombus in the Klf15-siRNA group was increased compared with that in the Klf15-NC group. As shown in Fig. 1C, compared with the Klf15-NC group, the Klf15-siRNA group with Klf15-siRNA injection (and thus with significantly reduced Klf15 expression) exhibited a significantly increased thrombus wet weight (Fig. 1D). Thus, Klf15 is significantly associated with thrombus formation and weight.

Table I

Number of successful injection of mice and successful modeling of DVT mice.

Table I

Number of successful injection of mice and successful modeling of DVT mice.

GroupBlankDVTKlf15-NCKlf15-siRNA
Sample size10101010
Number of successful injection of mice--98
Number of successful modeling of DVT mice-755

[i] si, small interfering; Klf15, Krüppel-like family 15; DVT, deep venous thrombosis.

RNA-seq results, data quality assessment and mapping

After performing the morphological experiments previously described, genetic analysis was conducted by RNA-seq, a method of high-throughput sequencing, to investigate transcriptional gene abundance and simultaneously study active regions of transcription.

Samples were divided into four groups: The Blank group, the DVT group, the Klf15-NC group (0.9% NS caudal vein injection) and the Klf15-siRNA group (Klf15-siRNA caudal vein injection). A total of ~25.8 and 28.1 million raw reads were collected from the DVT and Blank groups, respectively, while 29.6 and 30.3 million raw reads were obtained from the Klf15-NC and Klf15-siRNA groups, respectively. Then, further analysis was performed to obtain high-quality clean reads and the low-quality reads, which had either >50% of bases with a Q value ≤20 or >5% of unrecognized sequences ('N'), were discarded. Consequently, ~24.8 and 26.8 million high-quality clean reads were obtained from the DVT and Blank groups, respectively, 29.1 and 29.6 million high-quality clean reads were obtained from the Klf15-NC and Klf15-siRNA groups, respectively. Then, the clean reads were mapped to the human reference genome for downstream gene analyses. As a result, the rates of mapping for the DVT group and the Blank group were 89.40 and 90.22%, respectively, while the rates of mapping for the Klf15-NC group and the Klf15-siRNA group were 89.26 and 90.12%, respectively, which demonstrated the quality of the gene mapping. The results of the RNA-seq reads are listed in Table II and the mapping results are listed in Table III. The high-quality reads for different groups were collected for further analyses.

Table II

Quality assessment of the raw RNA-sequences reads results of the sequences.

Table II

Quality assessment of the raw RNA-sequences reads results of the sequences.

SampleRaw_readsClean_readsClean_basesError_rateQ20Q30GC_pct
DVT126177314256834597.71G0.0397.3992.9950.06
DVT223970627221646286.65G0.0397.0192.2850.38
DVT327492800266622178.0G0.0397.5593.5050.96
Blank130056705276719708.3G0.0397.7393.8150.95
Blank226587894261317607.84G0.0397.3092.8750.33
Blank327518969266230137.99G0.0396.9292.0350.23
Klf15-NC123873304233443877.0G0.0298.1994.7950.64
Klf15-NC331553809310616889.32G0.0298.2895.0751.05
Klf15-NC433418796328159079.84G0.0298.1994.8451.31
Klf15-siRNA_228443883276589948.3G0.0298.1894.8150.36
Klf15-siRNA_331256846305734989.17G0.0298.2694.9051.13
Klf15-siRNA_531209875304968599.15G0.0298.0594.4050.41

[i] si, small interfering; Klf15, Krüppel-like family 15; DVT, deep venous thrombosis; NC, negative control.

Table III

Read mapping results of the sequences

Table III

Read mapping results of the sequences

SampleTotal_readsTotal_map (%)Unique_map (%)Multi_map (%)Splice_map (%)
DVT15136691849046085 (95.48)46528972 (90.58)2517113 (4.9)17368593 (33.81)
DVT24432925641980259 (94.7)39085822 (88.17)2894437 (6.53)15925579 (35.93)
DVT35332443450898142 (95.45)47701078 (89.45)3197064 (6.0)19203249 (36.01)
Blank15534394053021663 (95.8)49481609 (89.41)3540054 (6.4)20032572 (36.2)
Blank25226352049811834 (95.31)47560000 (91.0)2251834 (4.31)18114051 (34.66)
Blank35324602650413825 (94.68)48052390 (90.25)2361435 (4.43)18879029 (35.46)
Klf15-NC14668877445469186 (97.39)42152166 (90.28)3317020 (7.1)16922773 (36.25)
Klf15-NC36212337660297028 (97.06)55302462 (89.02)4994566 (8.04)21761027 (35.03)
Klf15-NC46563181463630957 (96.95)58085965 (88.5)5544992 (8.45)23699020 (36.11)
Klf15-siRNA_25531798853743158 (97.15)50929624 (92.07)2813534 (5.09)19622245 (35.47)
Klf15-siRNA_36114699659683848 (97.61)53836311 (88.04)5847537 (9.56)22426460 (36.68)
Klf15-siRNA_56099371859329105 (97.27)55020590 (90.21)4308515 (7.06)21394177 (35.08)

[i] si, small interfering; Klf15, Krüppel-like family 15; NC, negative control; DEG, differentially expressed genes; DVT, deep venous thrombosis.

Correlation analysis, principal component analysis (PCA) and clustering analysis

To study the correlation and clustering of the transcript sequences, the FPKM method was used to evaluate the expression level of transcripts and the correlations between replicates, which were determined in each sample by utilizing the genetic length and the reads mapped to the human reference genome.

As shown in Fig. 2A and B, except for the Blank 1 group with an R2≤0.8, Pearson's correlation analysis indicated that the distribution of the FPKM values were significantly consistent for all replicates compared with each group (R2≥0.8).

Furthermore, PCA was performed to evaluate the differences among groups and the consistency of samples within groups, which were expected to be distant from each other in different groups and clustered within the same group. The Blank 1 group, the DVT 1 group and the Klf15-siRNA 3 group were discarded, as these groups exhibited poor correlations with their own groups. Thus, clustering analysis was performed on groups of samples that were further separated into subgroups according to the PCA results: The Blank group (Blank 2 and Blank 3), the DVT group (DVT 2 and DVT 3), the Klf15-siRNA group (Klf15-siRNA2 and Klf15-siRNA5) and the Klf15-NC group (NC1, NC3 and NC4). The clustering analysis showed repeatable and correlative characteristics in the data. The results of the clustering analysis demonstrated gene expression differences between the Blank group and the DVT group and between the Klf15-siRNA group and the Klf15-NC group (Fig. 2C and D).

Identification of DEGs

For analysis of gene expression and the DEGs, data processing was conducted with the essential conditions of an adjusted P<0.05 and log2-fold-change (FC) for the determination of gene regulation, which was log2FC>1 for upregulated genes and log2FC<-1 for down-regulated genes. In total, 2,206 DEGs were identified from the comparison of the DVT group and Blank group, including 1,330 upregulated genes and 876 downregulated genes, which are represented as red points and green points in the volcano plot, respectively (Fig. 3A). Gene expression analysis also revealed 1,041 DEGs between the Klf15-siRNA group and the Klf15-NC group, with 235 upregulated genes and 806 downregulated genes (Fig. 3B). The number of DEGs in each comparison is listed in Table IV. As shown in Table V, the expression levels of these genes showed significant differences in the DVT group compared with in the Blank group and the genes mainly clustered into three gene families; there were five genes in the Mmp family, four genes in the IL family, and 13 genes in the chemokine family. The expression levels of Mmp3, Mmp8, Mmp9, Mmp13 and Mmp19 in the DVT group were significantly increased compared with those in the Blank group. The expression of Mmp12 was also increased in the DVT group when compared with the Blank group; however, this finding was not significant. Genes in the interleukin (IL) family, including Il-lr2, Il-la, Il-lb and Il-6, were expressed more highly in the DVT group than in the Blank group. Moreover, the expression levels of genes in the Cc and Cx families of the DVT group were higher than those of the Blank group, except the expression level of Cc121a, which was lower in the DVT group than in the Blank group.

Table IV

The number of DEGs identified from four groups.

Table IV

The number of DEGs identified from four groups.

DEG setDEGsUpregulatedDownregulated
DVT_vs_Blank2,2061,330876
Klf15-siRNA_vs_NC1,041235806

[i] si, small interfering; Klf15, Krüppel-like family 15; DVT, deep venous thrombosis; NC, negative control; DEG, differentially expressed genes.

Table V

DEGs identified in a comparison of the DVT group and the Blank group by RNA-sequencing.

Table V

DEGs identified in a comparison of the DVT group and the Blank group by RNA-sequencing.

Gene_idDVTBlanklog2 Fold changePadjGene_name
ENSMUSG0000004972378.07766847.93960.7071390.566752Mmp12
ENSMUSG00000050578204.50464.8755475.391707 3.03×10−09Mmp13
ENSMUSG000000436133941.1668290.87743.759948 3.10×10−39Mmp3
ENSMUSG000000058003114.604863.949695.606005 1.10×10−10Mmp8
ENSMUSG000000177377694.2132732.72353.392543 1.06×10−29Mmp9
ENSMUSG000000253551703.9523203.57873.064868 1.52×10−13Mmp19
ENSMUSG000000260733607.806348.759416.20899 3.12×10−63Il1r2
ENSMUSG00000027399553.4439739.45373.811049 9.93×10−19Il1a
ENSMUSG000000273985679.7852139.79075.344781 9.60×10−76Il1b
ENSMUSG000000257461369.3955.7584267.893124 2.59×10−39Il6
ENSMUSG00000035352906.99266100.08863.17938 6.97×10−21Ccl12
ENSMUSG000000353853020.637495.410174.984662 1.14×10−08Ccl2
ENSMUSG000000946867.4708094119.9455−4.02534 2.10×10−06Ccl21a
ENSMUSG000000009823120.647931.870386.61243 3.97×10−76Ccl3
ENSMUSG000000189301205.035132.315765.220409 1.03×10−32Ccl4
ENSMUSG00000035042712.576842817.25−1.98337 1.21×10−11Ccl5
ENSMUSG000000189278371.46621210.4172.789986 1.64×10−44Ccl6
ENSMUSG000000353732485.737179.309414.970069 3.32×10−07Ccl7
ENSMUSG000000191225063.0309592.49133.095273 2.35×10−50Ccl9
ENSMUSG000000293802017.18219.951516.659775 1.9×10−104Cxcl1
ENSMUSG000000613536200.458210594.49−0.77288 4.82×10−05Cxcl12
ENSMUSG000000215083590.1969118.90114.916188 6.83×10−07Cxcl14
ENSMUSG00000018920523.29727975.7794−0.898480.00284Cxcl16
ENSMUSG0000005842716451.2310.2043610.65536 8.05×10−148Cxcl2
ENSMUSG000000293799750.57650.88682113.4245 9.92×10−35Cxcl3
ENSMUSG000000293713329.79224.4301659.552655 7.59×10−79Cxcl5
ENSMUSG00000029417721.6049682.63570.0797690.889672Cxcl9
ENSMUSG000000261803454.5181333.22023.3741 5.89×10−46Cxcr2
ENSMUSG000000453823109.524812.41511.93664 2.84×10−15Cxcr4
ENSMUSG00000048521152.50759568.3105−1.89793 1.83×10−07Cxcr6
ENSMUSG00000026691114.1127614.200973.0044070.005941Fmo3
ENSMUSG000000265801733.686129.04243.747548 5.07×10−28Selp
ENSMUSG000000462233734.2897435.49633.100282 1.12×10−47Plaur
ENSMUSG0000000541312311.935735.42734.065414 7.15×10−42Hmox1
ENSMUSG000000199879944.88638.992557.994212 1.56×10−176Arg1

[i] si, small interfering; Klf15, Krüppel-like family 15; DVT, deep venous thrombosis.

As shown in Table V, there were four DEGs (Selp, Plaur, Hmoxl and Argl) that were detected from the comparison between the DVT group and the Blank group, which correlated with the previously obtained results.

Notably, two DEGs were identified, Fmo3 and Mmp19, that had not been previously detected in DVT and are listed in Table V.

As shown in Table VI, three genes, Klf15, Mmp12 and Mmp13, showed higher expression in the Klf15-siRNA group than in the Klf15-NC group, except for the level of Klf15 itself due to the caudle vein injection of Klf15 siRNA in mice of the Klf15-siRNA group.

Table VI

Differentially expressed genes identified in a comparison of the Klf15-siRNA group and the Klf15-NC group.

Table VI

Differentially expressed genes identified in a comparison of the Klf15-siRNA group and the Klf15-NC group.

Gene_idsiRNANClog2 Fold changePadjGene_name
ENSMUSG00000030087100.70496301.1934−1.581550.000497Klf15
ENSMUSG00000049723647.4817101.93242.665213 6.61×10−05Mmp12
ENSMUSG00000050578401.39705115.94581.7962710.000549Mmp13

[i] si, small interfering; Klf15, Krüppel-like family 15; NC, negative control.

GO analysis of DEGs

Previously in this study, DEGs were identified among different groups. Thus, GO enrichment analysis was performed to discover the biological processes of these DEGs, which demonstrated significant functions of gene expression in different groups. Then, the GO terms were divided into three categories: Biological process (BP), cellular component (CC) and molecular function (MF).

As shown in Fig. 4A and B, the top 30 ranked GO terms of the comparison between the DVT group and the Blank group were selected for the bar graph and scatter plot. Consequently, 'leukocyte migration' was the most significantly enriched term. Then, 'positive regulation of locomotion', 'positive regulation of cell motility' and 'positive regulation of cell migration' accounted for the most enriched terms in the BP category. In addition, in Fig. 4C and D, the top 30 ranked GO terms from the comparison of the Klf15-siRNA group and the Klf15-NC group showed that 'axon, postsynapse' and 'presynapse' were the most highly enriched terms. At the same time, 'the regulation of ion transmembrane transport', 'signal release' and 'modulation of synaptic transmission' were abundant in both the CC category and the MF category.

Figure 4

Bubble diagram and bar diagram of the DEG GO terms. Bubble diagram of the top 20 ranked GO terms of the DEGs. In the bubble diagram, the vertical axis indicates GO terms and the horizontal axis represents the enrichment factor. The sizes of dots indicate the number of genes in the GO term. In the bar diagram, GO terms were divided into three categories: The red bar represents BP, the green bar represents CC and the blue bar indicates MF. (A) Bubble diagram of the top 30 ranked DEGs from the comparison between the Blank group and the DVT group. (B) Bar diagram of GO terms from the comparison between the Blank group and the DVT group. Bubble diagram and bar diagram of the DEG GO terms. Bubble diagram of the top 20 ranked GO terms of the DEGs. In the bubble diagram, the vertical axis indicates GO terms and the horizontal axis represents the enrichment factor. The sizes of dots indicate the number of genes in the GO term. In the bar diagram, GO terms were divided into three categories: The red bar represents BP, the green bar represents CC and the blue bar indicates MF. (C) Bubble diagram of the top 30 ranked DEGs from the comparison of the Klf15-NC group and the Klf15-siRNA group. (D) Bar diagram of GO terms from the comparison of the Klf15-NC group and the Klf15-siRNA group. si, small interfering; Klf15, Krüppel-like family 15; DVT, deep venous thrombosis; GO, gene ontology; BP, Biological process; MF, molecular function; CC, cellular component; DEGs, differentially expressed genes.

The results of the GO analysis revealed the distribution of genes in different biological functions, from which information regarding DEGs that may be beneficial to further study could be obtained.

KEGG pathway analysis of DEGs

To characterize the coordinative relations between genes and the roles of genes in biological functions, DEGs were analyzed by KEGG enrichment analysis, in which biochemical metabolic and signal transduction pathways were detected from the included DEGs.

The results in Table VII revealed that 50 pathways with significant expression (P<0.01) were identified in the comparison between the DVT group and the Blank group. In Fig. 5A and B, the top 20 ranked pathways are listed in the bar graph and bubble diagram; numerous signal transduction pathways were notably enriched, including the 'HIF-1 signaling pathway', 'Th17 cell differentiation', 'the intestinal immune network for IgA production', 'TNF signaling pathway', 'cell adhesion molecules (CAMs)', 'the PI3K-Akt signaling pathway', 'ECM-receptor interactions', 'the Jak-STAT signaling pathway' and 'the IL-17 signaling pathway'. Moreover, BP terms, including 'the cytokine-cytokine receptor interaction', 'hematopoietic cell lineage', 'Th17 cell differentiation', 'CAM', 'ECM-receptor interaction', 'glycolysis/gluconeogenesis', 'osteoclast differentiation', 'Staphylococcus aureus infection', 'Th1 and Th2 cell differentiation', and 'complement and coagulation cascade terms', were significantly enriched in the analysis.

Table VII

KEGG pathway enrichment analysis of the DVT group vs. the Blank group.

Table VII

KEGG pathway enrichment analysis of the DVT group vs. the Blank group.

KEGGIDDescriptionGene ratioBgRatioP-valueCountUpDown
mmu04060Cytokine-cytokine receptor interaction100/907234/6352 2.48×10−271006040
mmu04640Hematopoietic cell lineage50/90789/6352 1.65×10−20502624
mmu05323Rheumatoid arthritis30/90777/6352 7.01×10−0830219
mmu05144Malaria22/90747/6352 8.39×−0822202
mmu04066HIF-1 signaling pathway34/90799/6352 3.48×10−0734313
mmu04659Th17 cell differentiation34/90799/6352 3.48×10−07341321
mmu04672Intestinal immune network for IgA production19/90741/6352 7.86×10−0719415
mmu04668TNF signaling pathway35/907107/6352 8.86×10−0735323
mmu04514Cell adhesion molecules42/907146/6352 3.46×10−06421824
mmu04151PI3K-Akt signaling pathway75/907319/6352 4.15×10−06755124
mmu04512ECM-receptor interaction28/90782/6352 4.28×10−0628199
mmu04657IL-17 signaling pathway29/90787/6352 5.01×10−0629272
mmu00010 Glycolysis/gluconeogenesis23/90762/6352 6.36×10−0623194
mmu04380Osteoclast differentiation36/907123/6352 1.13×10−0536342
mmu05140Leishmaniasis23/90765/6352 1.58×10−0523176
mmu05150Staphylococcus aureus infection18/90745/6352 1.95×10−0518126
mmu04658Th1 and Th2 cell differentiation27/90785/6352 2.85×10−0527720
mmu04610Complement and coagulation cascades24/90773/6352 4.20×10−0524195
mmu05321Inflammatory bowel disease20/90757/6352 6.44×10−05201010
mmu04630Jak-STAT signaling pathway38/907143/6352 7.05×10−05382513
mmu05152Tuberculosis41/907160/6352 9.04×10−05412912
mmu04064NF-κB signaling pathway27/90792/63520.0001319271611
mmu05340Primary immunodeficiency14/90735/63520.000164514014
mmu05202Transcriptional misregulation in cancer41/907169/63520.0003243412714
mmu05162Measles32/907122/63520.0003335321913
mmu04010MAPK signaling pathway61/907281/63520.0003692614912
mmu05166HTLV-I infection57/907262/63520.0005396573126
mmu05164Influenza A36/907147/63520.000610536279
mmu00052Galactose metabolism12/90731/63520.000685712111
mmu05418Fluid shear stress and atherosclerosis34/907138/63520.000763934313
mmu05320Autoimmune thyroid disease16/90750/63520.001095516610
mmu00220Arginine biosynthesis8/90717/63520.001229862
mmu05145Toxoplasmosis27/907105/63520.0013127271512
mmu04062Chemokine signaling pathway40/907176/63520.0015037402713
mmu04216Ferroptosis13/90739/63520.002087613112
mmu04612Antigen processing and presentation20/90774/63520.002860320911
mmu05332Graft-versus-host disease15/90750/63520.00316911578
mmu05133Pertussis19/90770/63520.003422719172
mmu04145Phagosome35/907156/63520.0036189352510
mmu04621NOD-like receptor signaling pathway34/907151/63520.003860334304
mmu05134Legionellosis16/90756/63520.004029516151
mmu00590Arachidonic acid metabolism17/90761/63520.004087717143
mmu04620Toll-like receptor signaling pathway22/90787/63520.004424122193
mmu05230Central carbon metabolism in cancer17/90762/63520.004902117161
mmu05330Allograft rejection14/90748/63520.005683214410
mmu04940Type I diabetes mellitus15/90753/63520.00581931569
mmu04931Insulin resistance25/907105/63520.005861625187
mmu05310Asthma8/90721/63520.0060726817
mmu05142Chagas disease (American trypanosomiasis)24/907100/63520.006175224186
mmu01230Biosynthesis of amino acids18/90770/63520.007955818153

[i] KEGG, Kyoto Encyclopedia of Genes and Genomes; DVT, deep venous thrombosis.

In the comparison between the Klf15-siRNA group and the Klf15-NC group, 23 pathways with significant expression (P<0.01) were identified and are listed in Table VIII. The top 20 ranked pathways are shown in Fig. 5C and D. The results revealed that several signal transduction pathways were significantly enriched, including 'the PI3K-Akt signaling pathway', 'the Hippo signaling pathway', 'the cAMP signaling pathway' and 'the relaxin signaling pathway'. In addition, BP terms were identified; these terms included 'the cholinergic synapse', 'neuroactive ligand-receptor interaction', 'ECM-receptor interaction', 'dopaminergic synapse', 'nicotine addiction', 'rheumatoid arthritis', 'synaptic vesicle cycle', 'taste transduction', 'vascular smooth muscle contraction', 'hypertrophic cardiomyopathy (HCM)', 'serotonergic synapse', 'mucin type O-glycan biosynthesis', 'dilated cardio-myopathy (DCM)' and 'protein digestion and absorption' terms. Among these terms, the 'vascular smooth muscle contraction', 'HCM' and 'DCM' terms provide crucial information regarding the roles of Klf15 in the formation and pathophysiological processes of vascular disease, especially DVT.

Table VIII

KEGG Pathways enrichment analysis of KLF15-siRNA group vs. KLF15-NC group.

Table VIII

KEGG Pathways enrichment analysis of KLF15-siRNA group vs. KLF15-NC group.

KEGGIDDescriptionGene ratioBgRatioP-valueCountUpDown
mmu04514Cell adhesion molecules25/352144/6351 2.50×10−0725817
mmu04725Cholinergic synapse20/352107/6351 1.23×10−0620020
mmu04080Neuroactive ligand-receptor interaction30/352225/6351 5.42×10−0630327
mmu04512ECM-receptor interaction15/35282/6351 3.52×10−0515015
mmu04728Dopaminergic synapse19/352126/6351 5.60×10−0519019
mmu05033Nicotine addiction8/35235/63510.0005167808
mmu05323Rheumatoid arthritis12/35276/63510.00086451284
mmu04151PI3K-Akt signaling pathway32/352325/63510.000971732527
mmu04721Synaptic vesicle cycle10/35259/63510.00132261019
mmu04742Taste transduction9/35250/63510.0014766909
mmu04270Vascular smooth muscle contraction15/352115/63510.001591215114
mmu05410Hypertrophic cardiomyopathy12/35282/63510.001711212111
mmu04390Hippo signaling pathway18/352152/63510.001747518117
mmu04726Serotonergic synapse14/352106/63510.002002414014
mmu00512Mucin type O-glycan biosynthesis6/35226/63510.0024822615
mmu05414Dilated cardiomyopathy12/35286/63510.002587612012
mmu04024cAMP signaling pathway20/352186/63510.00318120020
mmu05321Inflammatory bowel disease9/35256/63510.003331972
mmu04974Protein digestion and absorption11/35278/63510.00354691129
mmu05144Malaria8/35247/63510.0038607826
mmu04727GABAergic synapse11/35279/63510.003921911011
mmu04911Insulin secretion11/35279/63510.003921911110
mmu04926Relaxin signaling pathway15/352126/63510.003925915114

[i] KEGG, Kyoto Encyclopedia of Genes and Genomes; DVT, deep venous thrombosis; si, small interfering; NC, negative control.

qPCR validation of DEGs

Next, to confirm the results of the DEG analyses, eight significant DEGs were selected from the RNA-seq results from the comparison of the DVT and Blank groups for further qPCR validation. As shown in Fig. 6, the expression levels of Mmp12 and Mmp13 in the DVT group were significantly increased compared with those in the Blank group. The expression level of Klf15 in the DVT group decreased significantly compared with that in the Blank group. Moreover, the levels of Mmp 19, Arg1, Ccl2, Fmo3 and Hmox1 in the DVT group were all significantly increased compared with those in the Blank group, which demonstrated the correlation of the results.

Discussion

DVT is one of the most common vascular diseases and has a high mortality rate (1). Nevertheless, the current diagnostic and therapeutic methods are limited (18). In current DVT studies, the mechanism and regulatory factors involved in the formation and pathological process of DVT should be investigated to provide a foundation for the diagnosis and treatment of DVT (19).

Klf15 was shown to be closely related to cardiovascular diseases such as hypertension, atherosclerosis and coronary heart disease (20). Klf15 is a transcriptional regulatory factor involved in various functions, including cell differentiation, apoptosis and tumor formation, and is expressed in various tissues and organs, including the heart, liver, and kidneys (21). Moreover, Klf15 plays a key role in the development of atherosclerosis (12). According to the authors' preliminary experiments, it was found that Klf15 might also affect thrombosis. To promote knowledge about the relationship and genetic interaction between DVT and Klf15, this study was performed.

Numerous obstacles prevent the complete understanding of the pathology, diagnosis and treatment of DVT. The present study aimed to examine factors regulating the initiation and progression of DVT and factors related to effective and utilizable measures.

To the best of our knowledge, this is the first study to perform high-throughput sequencing in a mouse DVT model and to investigate the effect of Klf15 on DVT formation. The data and analyses in the current study suggest that pathways including TNF, PI3K-Akt, IL-17, Jak-STAT, NF-κB, and MAPK should be considered, as such pathways were correlated with the formation of thrombi according to the KEGG enrichment analysis of the DEGs between the DVT and Blank groups. Previous studies (22,23) have reported that MAPK pathways are related to vascular endothelial venous thrombosis and our colleagues have suggested that resveratrol may exert an in vitro antithrombotic activity by inactivating MAPK signaling pathways (24). Moreover, KEGG analysis of the comparison of the Klf15-siRNA group and the Klf15-NC group indicated that PI3K-Akt play a central role in the regulatory pathway involved in DVT formation.

The DEGs revealed by these comparisons indicated the crucial role of certain genes in the regulation of DVT. In the comparison of the DVT and Blank groups, the identified genes ranged from members of the Mmp family, the IL family, and the chemokine family to Selp, Plaur, Hmox 1 and Arg1. Fonseca et al (25) indicated that Mmp plays a critical role in numerous cellular processes. Li et al (26) discovered that Mmp3 polymorphisms and upregulated protein expression in the Chinese Han population may provide new markers associated with the evaluation of DVT diagnosis and risk. Lenglet et al (27) performed a study on mice by subjecting their brains to ischemic stroke and revealed differentially expressed levels of Mmp family genes, including significantly upregulated expression of Mmp9, 10, and 13 and Timp1. Xiao et al (28) indicated that Mmp8 enhanced vascular smooth muscle cell (VSMC) proliferation and played an important role in neointima formation via ADAM10-, N-cadherin-, and β-catenin-mediated pathways. Mmp8 enhances VSMC proliferation, according to a study of WT and Mmp9-/- mice that underwent stasis venous thrombosis (VT) by ligation of the IVC. The tissues were harvested at different time points and the results showed that the midterm vein wall collagen content was regulated by Mmp9 (28). Thus, Mmp9 plays a role in both vein wall responses and late thrombus resolution. Quillard et al (29) found that Mmp13 prevailed over Mmp8 in collagen degradation in atheromata, thus identifying a selective target for plaque structure formation. Based on the current analysis and previous reports, the present study believes that the role of the MMP family in DVT deserves further study.

Genes in the IL family were identified, including Il-lr2, Il-la, Il-lb and Il-6, that showed higher expression in the DVT group than in the Blank group. Gupta et al (30) demonstrated the increased expression of NLRP3, caspase-1 and IL-1β in individuals with clinically established VT. van Minkelen et al (31) found that IL1RN-H5H5 carriership increases the risk of VT. Analyses of the DEGs in the chemokine families revealed that these DEGs had generally higher expression in the DVT group than in the Blank group, with the exception of some members mentioned in qPCR Validation of DEGs. Among those genes in the Cc and Cx families, a study of Cxcr2 was previously performed. Henke et al (32) found that normal DVT resolution involved Cxcr2-mediated neovascularization, collagen turn-over and fibrinolysis and that this process is probably primarily monocyte-dependent. Henke and Wakefield (33) indicated that early thrombus resolution primarily involves Cxcr2-associated plasmin activation and Mmp-9, while later resolution involves both Cxcr2- and Ccr2-mediated uPA cell influx and thrombus angiogenesis. According to the above reports and our data, inflammation plays an important role in the formation of DVT. The present study speculated that Ccl2, a downstream gene of Klf15, may be the key factor in the effects of Klf15 on DVT formation.

A study of the relationship between Hmox1 and DVT was conducted by Bean et al (34) who identified a critical cytoprotective enzyme encoded by the inducible Hmox1 gene with anti-inflammatory, antioxidant and anticoagulant activities in the vascular system. A (GT)n microsatellite located in the promoter of the Hmox1 gene influences the level of the response. Peng et al (35) stimulated HO-1 (Hmox1) production and revealed the inhibition of platelet-dependent thrombus formation in HO-1−/− mice compared with that in WT mice, and this inhibition may represent an adaptive response mechanism to reduce platelet activation.

Bojic et al (36) conducted a study on mice regarding the relationships between the peroxisome proliferator-activated receptor (PPAR)δ agonist GW1516 in aortic inflammation and atherosclerosis via intervention by the PPARδ agonist; this study revealed that the progression of preestablished atherosclerosis was inhibited by aortic inflammation and attenuated by the progression of preestablished atherosclerosis. Furthermore, GW1516 intervention decreased the expression of aortic proinflammatory M1 cytokines, increased the expression of the anti-inflammatory M2 cytokine Arg1 and attenuated the iNos/Arg1 ratio. Samsoondar et al (37) performed hepatic gene expression analysis on Ldlr/− mice fed a high-fat, high-cholesterol diet (42% kcal fat, 0.2% cholesterol) supplemented with bempedoic acid at 0, 3, 10 and 30 mg/kg body weight. These results showed that in the full-length aorta, bempedoic acid markedly suppressed cholesteryl ester accumulation, attenuated the expression of proinflammatory M1 genes and attenuated the iNos/Arg1 ratio, which demonstrated that Ccl3 and Nos2 are marker genes for M1 macrophages and that Arg1 may be a marker gene for M2 macrophages. To the best of our knowledge, research and papers on the role of Arg1 in thrombosis are scarce but based on the current data, it suggests that Arg1 should be studied.

The present study first identified the critical roles of Fmo3 and Mmp19 in regulating DVT. Zhu et al (38) demonstrated that the microbe-dependent production of trimethylamine N-oxide (TMAO) contributes to the risk of thrombosis. Thus, a murine FeCl3-induced carotid artery injury model was established to confirm the impact of FMO3 suppression [via antisense oligonucleotide (ASO) targeting] and overexpression (as a transgene), which was examined by the plasma TMAO levels, platelet responsiveness and thrombosis potential. The present study demonstrated that host hepatic FMO3, the final product of the metaorganismal TMAO pathway, participates in diet- and gut microbiota-dependent changes in both platelet responsiveness and thrombosis potential in vivo (37). Shih et al (39) treated WT and FMO3KO mice with control or FMO-3 ASOs. FMO-3-ASO treatment led to the same extent of lipid-lowering effects in the FMO3KO mice as it did in the WT mice, indicating off-target effects. This study revealed that both FMO3KO and WT mice fed a 0.5% choline diet showed a substantial reduction in both TMAO and in vivo thrombosis potential.

In conclusion, a transcriptome study consisting of two parts was performed to investigate the expression levels of Klf15 and other related genes in C57BL/6 mice with IVC thrombi for the first time. The experimental results indicated that 2,206 genes were differentially expressed between the DVT group and the Blank group, and 1,041 DEGs were identified by comparing the Klf15-siRNA group with the Klf15-NC group. The present study confirmed that Arg1, Ccl2 and Hmox1 are related to DVT, as previously identified, and new genes related to the formation of DVT were identified, including Fmo3 and Mmp19. Furthermore, to the best of our knowledge, the present study is the first to reveal that genes such as Mmp12 and Mmp13 are involved in the regulation of DVT; the current results obtained via comparison of the Klf15-siRNA group and the Klf15-NC group are especially revealing. Given the data obtained in the present experiments, it is speculated that Klf15 may play a role in DVT by regulating inflammatory genes, some members of the MMP family or other DEGs; however, this speculation needs to be confirmed in the future. In the next study, cell experiments, clinical experiments and additional animal experiments will be performed to confirm the role of Klf15 in DVT, including pathway regulation and whether DVT formation is regulated by Klf15 via Mmp12 and Mmp13. The present research provides new insights and prospects for studying the mechanism of thrombosis and possible drug targets.

Acknowledgements

Not applicable.

Funding

The present study was supported by the National Natural Science Foundation of China (Grant. Nos. 81760029 and 81760030) and the Health Science and Technology Project of Yunnan Province (Grant. Nos. 2017NS021 and 2018NS0106).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Authors' contributions

XZ and RZ conceived the present study. RZ designed the experiments. JZ and SX prepared the materials and conducted the experiments on mice with IVC thrombi. XZ processed the data. RZ contributed substantially to the data analysis and manuscript revision. All authors read and approved the final manuscript.

Ethics approval and consent to participate

All animal experiments were performed following approval from the Animal Experimental Ethical Committee of Kunming Medical University (Kunming, China).

Patient consent for publication

Not applicable.

Competing interest

The authors declare that they have no conflicts of interest.

References

1 

Huerta C, Johansson S, Wallander MA and García Rodríguez LA: Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med. 167:935–943. 2007. View Article : Google Scholar : PubMed/NCBI

2 

Zhu L, Cheng J, Gu P, Liu Y, Liu J, Wang J and Shen H: Therapeutic strategies of thromboembolic events in patients with inflammatory bowel diseases: Two case reports. Medicine (Baltimore). 98:e146222019. View Article : Google Scholar

3 

Kandic Z, Firdus N, Kandic A, Catic L and Kandic E: Treatment of the rectal cancer in casuistic clinic for abdominal surgery, Clinical centre of the University of Sarajevo (2006-2010). Acta Chir Iugosl. 59:97–101. 2012. View Article : Google Scholar

4 

Leenders JJ, Wijnen WJ, van der Made I, Hiller M, Swinnen M, Vandendriessche T, Chuah M, Pinto YM and Creemers EE: Repression of cardiac hypertrophy by KLF15: Underlying mechanisms and therapeutic implications. PLoS One. 7:e367542012. View Article : Google Scholar : PubMed/NCBI

5 

Payne H, Ponomaryov T, Watson SP and Brill A: Mice with a deficiency in CLEC-2 are protected against deep vein thrombosis. Blood. 129:2013–2020. 2017. View Article : Google Scholar : PubMed/NCBI

6 

Brill A, Fuchs TA, Chauhan AK, Yang JJ, De Meyer SF, Köllnberger M, Wakefield TW, Lämmle B, Massberg S and Wagner DD: Von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models. Blood. 117:1400–1407. 2011. View Article : Google Scholar :

7 

Fan L, Hsieh PN, Sweet DR and Jain MK: Krüppel-like factor 15: Regulator of BCAA metabolism and circadian protein rhythmicity. Pharmacol Res. 130:123–126. 2018. View Article : Google Scholar

8 

Lu Y, Zhang L, Liao X, Sangwung P, Prosdocimo DA, Zhou G, Votruba AR, Brian L, Han YJ, Gao H, et al: Kruppel-like factor 15 is critical for vascular inflammation. J Clin Invest. 123:4232–4241. 2013. View Article : Google Scholar : PubMed/NCBI

9 

Trapnell C, Pachter L and Salzberg SL: TopHat: Discovering splice junctions with RNA-Seq. Bioinformatics. 25:1105–1111. 2009. View Article : Google Scholar : PubMed/NCBI

10 

Cui JY and Klaassen CD: RNA-Seq reveals common and unique PXR-and CAR-target gene signatures in the mouse liver transcriptome. Biochim Biophys Acta. 1859:1198–1217. 2016. View Article : Google Scholar : PubMed/NCBI

11 

Lu Y, Haldar S, Croce K, Wang Y, Sakuma M, Morooka T, Wang B, Jeyaraj D, Gray SJ, Simon DI and Jain MK: Kruppel-like factor 15 regulates smooth muscle response to vascular injury-brief report. Arterioscler Thromb Vasc Biol. 30:1550–1552. 2010. View Article : Google Scholar : PubMed/NCBI

12 

Liu B, Xu L, Yu X, Li W, Sun X, Xiao S, Guo M and Wang H: Protective effect of KLF15 on vascular endothelial dysfunction induced by TNF-α. Mol Med Rep. 18:1987–1994. 2018.PubMed/NCBI

13 

Mackman N: Triggers, targets and treatments for thrombosis. Nature. 451:914–918. 2008. View Article : Google Scholar : PubMed/NCBI

14 

Yuping Y, Hua C and Qing Z: Advances in the relationship between Kruppel-like factor 15 and cardiovascular disease research. Cardiovasc Endocrinol Metab. 7:37–41. 2018. View Article : Google Scholar : PubMed/NCBI

15 

Mackman N: New insights into the mechanisms of venous thrombosis. J Clin Invest. 122:2331–2336. 2012. View Article : Google Scholar : PubMed/NCBI

16 

Li G, Zhou R, Zhao X, Liu R and Ye C: [Corrigendum] Correlation between the expression of IL-18 and deep venous thrombosis. Int J Mol Med. August 27–2018.Epub ahead of print.

17 

Yu G, Wang LG, Han Y and He QY: ClusterProfiler: An R package for comparing biological themes among gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI

18 

Lee AY and Hirsh J: Diagnosis and treatment of venous thromboembolism. Annu Rev Med. 53:15–33. 2002. View Article : Google Scholar : PubMed/NCBI

19 

Machlus KR, Aleman MM and Wolberg AS: Update on venous thromboembolism: Risk factors, mechanisms, and treatments. Arterioscler Thromb Vasc Biol. 31:476–478. 2011. View Article : Google Scholar : PubMed/NCBI

20 

Haldar SM, Lu Y, Jeyaraj D, Kawanami D, Cui Y, Eapen SJ, Hao C, Li Y, Doughman YQ, Watanabe M, et al: Klf15 deficiency is a molecular link between heart failure and aortic aneurysm formation. Sci Transl Med. 2:26ra262010. View Article : Google Scholar : PubMed/NCBI

21 

Noack C, Haupt LP, Zimmermann WH, Streckfuss-Bömeke K and Zelarayán LC: Generation of a KLF15 homozygous knockout human embryonic stem cell line using paired CRISPR/Cas9n, and human cardiomyocytes derivation. Stem Cell Res. 23:127–131. 2017. View Article : Google Scholar : PubMed/NCBI

22 

Jiang Z, Ma J, Wang Q, Wu F, Ping J and Ming L: Circulating microRNA expression and their target genes in deep vein thrombosis: A systematic review and bioinformatics analysis. Medicine (Baltimore). 96:e93302017. View Article : Google Scholar

23 

Noble S and Pasi J: Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer. 102(Suppl 1): S2–S9. 2010. View Article : Google Scholar : PubMed/NCBI

24 

Lou Z, Li X, Zhao X, Du K, Li X and Wang B: Resveratrol attenuates hydrogen peroxide-induced apoptosis, reactive oxygen species generation, and PSGL-1 and VWF activation in human umbilical vein endothelial cells, potentially via MAPK signalling pathways. Mol Med Rep. 17:2479–2487. 2018.

25 

Fonseca FL, da Costa Aguiar Alves B, Azzalis LA and Belardo TM: Matrix metalloproteases as biomarkers of disease. Methods Mol Biol. 1579:299–311. 2017. View Article : Google Scholar : PubMed/NCBI

26 

Li XP, Wan GZ, Wang GJ and Li JF: MMP3-1171 5A/6A promoter genotype influences serum MMP3 levels and is associated with deep venous thrombosis. Ann Vasc Surg. 34:261–267. 2016. View Article : Google Scholar : PubMed/NCBI

27 

Lenglet S, Montecucco F, Mach F, Schaller K, Gasche Y and Copin JC: Analysis of the expression of nine secreted matrix metalloproteinases and their endogenous inhibitors in the brain of mice subjected to ischaemic stroke. Thromb Haemost. 112:363–378. 2014. View Article : Google Scholar : PubMed/NCBI

28 

Xiao Q, Zhang F, Grassia G, Hu Y, Zhang Z, Xing Q, Yin X, Maddaluno M, Drung B, Schmidt B, et al: Matrix metallopro-teinase-8 promotes vascular smooth muscle cell proliferation and neointima formation. Arterioscler Thromb Vasc Biol. 34:90–98. 2014. View Article : Google Scholar

29 

Quillard T, Araújo HA, Franck G, Tesmenitsky Y and Libby P: Matrix metalloproteinase-13 predominates over matrix metal-loproteinase-8 as the functional interstitial collagenase in mouse atheromata. Arterioscler Thromb Vasc Biol. 34:1179–1186. 2014. View Article : Google Scholar : PubMed/NCBI

30 

Gupta N, Sahu A, Prabhakar A, Chatterjee T, Tyagi T, Kumari B, Khan N, Nair V, Bajaj N, Sharma M and Ashraf MZ: Activation of NLRP3 inflammasome complex potentiates venous thrombosis in response to hypoxia. Proc Natl Acad Sci USA. 114:4763–4768. 2017. View Article : Google Scholar : PubMed/NCBI

31 

van Minkelen R, de Visser MC, Houwing-Duistermaat JJ, Vos HL, Bertina RM and Rosendaal FR: Haplotypes of IL1B, IL1RN, IL1R1, and IL1R2 and the risk of venous thrombosis. Arterioscler Thromb Vasc Biol. 27:1486–1491. 2007. View Article : Google Scholar : PubMed/NCBI

32 

Henke PK, Varga A, De S, Deatrick CB, Eliason J, Arenberg DA, Sukheepod P, Thanaporn P, Kunkel SL, Upchurch GR Jr and Wakefield TW: Deep vein thrombosis resolution is modulated by monocyte CXCR2-mediated activity in a mouse model. Arterioscler Thromb Vasc Biol. 24:1130–1137. 2004. View Article : Google Scholar : PubMed/NCBI

33 

Henke PK and Wakefield T: Thrombus resolution and vein wall injury: Dependence on chemokines and leukocytes. Thromb Res. 123(Suppl 4): S72–S78. 2009. View Article : Google Scholar : PubMed/NCBI

34 

Bean CJ, Boulet SL, Ellingsen D, Trau H, Ghaji N, Hooper WC and Austin H: Increased risk of venous thromboembolism is associated with genetic variation in heme oxygenase-1 in Blacks. Thromb Res. 130:942–947. 2012. View Article : Google Scholar : PubMed/NCBI

35 

Peng L, Mundada L, Stomel JM, Liu JJ, Sun J, Yet SF and Fay WP: Induction of heme oxygenase-1 expression inhibits platelet-dependent thrombosis. Antioxid Redox Signal. 6:729–735. 2004. View Article : Google Scholar : PubMed/NCBI

36 

Bojic LA, Burke AC, Chhoker SS, Telford DE, Sutherland BG, Edwards JY, Sawyez CG, Tirona RG, Yin H, Pickering JG and Huff MW: Peroxisome proliferator-activated receptor δ agonist GW1516 attenuates diet-induced aortic inflammation, insulin resistance, and atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol. 34:52–60. 2014. View Article : Google Scholar

37 

Samsoondar JP, Burke AC, Sutherland BG, Telford DE, Sawyez CG, Edwards JY, Pinkosky SL, Newton RS and Huff MW: Prevention of diet-induced metabolic dysregulation, inflammation, and atherosclerosis in Ldlr−/− mice by treatment with the ATP-citrate lyase inhibitor bempedoic acid. Arterioscler Thromb Vasc Biol. 37:647–656. 2017. View Article : Google Scholar : PubMed/NCBI

38 

Zhu W, Buffa JA, Wang Z, Warrier M, Schugar R, Shih DM, Gupta N, Gregory JC, Org E, Fu X, et al: Flavin monooxygenase 3, the host hepatic enzyme in the metaorganismal trimethylamine N-oxide-generating pathway, modulates platelet responsiveness and thrombosis risk. J Thromb Haemost. 16:1857–1872. 2018. View Article : Google Scholar : PubMed/NCBI

39 

Shih DM, Zhu W, Schugar RC, Meng Y, Jia X, Miikeda A, Wang Z, Zieger M, Lee R, Graham M, et al: Genetic deficiency of flavin-containing monooxygenase 3 (Fmo3) protects against thrombosis but has only a minor effect on plasma lipid levels-brief report. Arterioscler Thromb Vasc Biol. 39:1045–1054. 2019. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June-2020
Volume 45 Issue 6

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhou J, Zhao X, Xie S and Zhou R: Transcriptome analysis of Klf15‑mediated inhibitory functions in a mouse deep venous thrombosis model. Int J Mol Med 45: 1735-1752, 2020.
APA
Zhou, J., Zhao, X., Xie, S., & Zhou, R. (2020). Transcriptome analysis of Klf15‑mediated inhibitory functions in a mouse deep venous thrombosis model. International Journal of Molecular Medicine, 45, 1735-1752. https://doi.org/10.3892/ijmm.2020.4538
MLA
Zhou, J., Zhao, X., Xie, S., Zhou, R."Transcriptome analysis of Klf15‑mediated inhibitory functions in a mouse deep venous thrombosis model". International Journal of Molecular Medicine 45.6 (2020): 1735-1752.
Chicago
Zhou, J., Zhao, X., Xie, S., Zhou, R."Transcriptome analysis of Klf15‑mediated inhibitory functions in a mouse deep venous thrombosis model". International Journal of Molecular Medicine 45, no. 6 (2020): 1735-1752. https://doi.org/10.3892/ijmm.2020.4538